Bristol-Myers Squibb Company
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMY research report →
Companywww.bms.com
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- CEO
- Christopher S. Boerner
- IPO
- 1972
- Employees
- 34,100
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $119.54B
- P/E
- 16.44
- P/S
- 2.47
- P/B
- 5.96
- EV/EBITDA
- 11.21
- Div Yield
- 4.27%
Profitability
- Gross Margin
- 68.75%
- Op Margin
- 25.67%
- Net Margin
- 15.01%
- ROE
- 39.05%
- ROIC
- 13.55%
Growth & Income
- Revenue
- $48.19B · -0.22%
- Net Income
- $7.05B · 178.82%
- EPS
- $3.46 · 178.46%
- Op Income
- $12.70B
- FCF YoY
- -7.87%
Performance & Tape
- 52W High
- $62.89
- 52W Low
- $42.52
- 50D MA
- $58.43
- 200D MA
- $52.59
- Beta
- 0.26
- Avg Volume
- 11.75M
Get TickerSpark's AI analysis on BMY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Lenkowsky Adam | other | 1,373 |
| May 1, 26 | Lenkowsky Adam | other | 203 |
| May 1, 26 | Lenkowsky Adam | other | 599 |
| May 1, 26 | Lenkowsky Adam | other | 1,373 |
| Apr 1, 26 | Shanahan Karin | other | 3,307 |
| Apr 1, 26 | Shanahan Karin | other | 1,692 |
| Apr 1, 26 | Shanahan Karin | other | 3,307 |
| Apr 1, 26 | Elkins David V | sell | 25,519 |
| Apr 1, 26 | Elkins David V | sell | 4,481 |
| Mar 31, 26 | YALE PHYLLIS R | other | 577.082 |
Our BMY Coverage
We haven't published any research on BMY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BMY Report →